Tranexamic acid - Leading BioSciences

Drug Profile

Tranexamic acid - Leading BioSciences

Alternative Names: InflammaGen Shok-Pak; LB-1148

Latest Information Update: 28 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Leading BioSciences
  • Developer Leading BioSciences; VA San Diego Healthcare System
  • Class Antifibrinolytics; Antihaemorrhagics; Cyclohexanecarboxylic acids; Skin disorder therapies; Small molecules
  • Mechanism of Action Serine protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cardiogenic shock; Post-surgical adhesions; Postoperative ileus; Septic shock
  • Phase I Haemorrhagic shock

Most Recent Events

  • 27 Mar 2017 Phase-I clinical trials in Haemorrhagic shock in USA (Enteral) (Leading Biosciences Pipeline, March 2017)
  • 27 Mar 2017 Phase-II development for Cardiovascular surgery complications is ongoing in Taiwan
  • 27 Mar 2017 Phase-II development for Septic shock is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top